API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The agreement facilitates the transition of the manufacturing process of recombinant GAD65, to a new manufacturer for future anticipated commercial manufacture.
Lead Product(s): Diamyd
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Protein Sciences Corporation
Deal Size: $5.0 million Upfront Cash: $5.0 million
Deal Type: Agreement February 05, 2020